CAMBRIDGE, Mass., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Leerink Swann Rare Disease Roundtable in New York City. Marc Beer, CEO of Aegerion, is scheduled to present on Wednesday, October 2, 2013 at 2:40 p.m. ET. The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the " Investors" section of Aegerion's website, www.aegerion.com . About Aegerion Pharmaceuticals Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com .
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Manager, Investor Relations 857-242-5024